Active — Not RecruitingPhase 4

The Effects of Dupilumab on Allergic Contact Dermatitis

United States17 participantsStarted 2019-12-18

Plain-language summary

The aim of this study is to investigate the effects of dupilumab on allergic contact dermatitis.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. At least 18 years of age
✓. At least one contact allergen with a 2+ (strong) or 3+ (extreme reaction) confirmed by patch testing within 6 months of the baseline visit that can be duplicated at the initiation of the study (placement at Week 0 and patch test reaction read at Week 0 +72-120 hours).
✓. Allergic contact dermatitis diagnosed clinically by the principle investigators who have expertise in allergic contact dermatitis
✓. Investigator's global assessment score of at least 3 (range 0-4) at the screening and baseline visits
✓. Documented recent history (within 18 months of patch testing) of inadequate response to treatment with topical medications and allergen avoidance
✓. Able and willing to provide informed consent, participate in study visits, and undergo visit procedures

Exclusion criteria

✕. Prior dupilumab use
✕. Treatment with a systemic immune-regulating medication within 3 months of the baseline visit or the patient's prior patch testing, whichever is longer. Examples of these medications include azathioprine, methotrexate, mycophenolate mofetil, Janus kinase inhibitors, and phototherapy (including tanning booths). Cyclosporine or prednisone may not have been used within 1 month of the baseline visit.
✕. Treatment with other biologic agents, such as TNF inhibitors, anti-IL 17 agents, anti-IL 12/23 agents, or anti-IL 23 agents, within 4 months of baseline visit or the patient's prior patch testing, whichever is longer.
✕. Use of rituximab within at 6 months (or until lymphocyte counts have normalized if longer than 6 months) of the baseline visit or the patient's prior patch testing, whichever is longer.
✕. Treatment with topical corticosteroids or topical calcineurin inhibitors within 1 week before the baseline visit
✕. Other active conditions, such as psoriasis, that may confound clinical evaluations of dermatitis and patient-reported symptoms
✕. Increased risk of infection or reactivated infection, including history of human immunodeficiency virus, hepatitis B, hepatitis C, endoparasitic infections, receipt of a live attenuated vaccine within 3 months of the baseline visit, chronic or acute infection requiring treatment within 4 weeks of the baseline visit, immunosuppressed status (ie recurrent or resistant opportunistic infections)
✕. Malignancy within 5 years of the screening visit excluding local cutaneous squamous cell carcinoma, basal cell carcinoma or cervical carcinoma in situ that has been fully treated.

What they're measuring

Change From Baseline in Investigator's Global Assessment (IGA) Score

Timeframe: week 0, week 6, week 12

Trial details

NCT IDNCT03935971

SponsorBrigham and Women's Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-12-31

Results submitted2025-12-24

View on ClinicalTrials.gov More Allergic Contact Dermatitis trials